Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcoma: Retrospective analysis and identification of prognostic factors in 488 patients
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND.: The efficacy of palliative chemotherapy was investigated in a large group of patients with advanced soft‐tissue sarcomas (STS) treated on routine palliative protocols. METHODS.: Patients with STS who had first‐line chemotherapy for advanced and/or metastatic disease between 1991 and 2005 were identified from the Royal Marsden Hospital's sarcoma database. Patients with Ewing sarcoma, rhabdomyosarcoma, desmoplastic small round cell tumor, and gastrointestinal stromal tumors were excluded from the study. RESULTS.: In all, 488 patients (242 male, 246 female) fulfilled the study criteria. The median age was 49 years and the majority (83%) received chemotherapy for metastatic disease. The most common histologic subtypes were leiomyosarcoma (35%) synovial sarcoma (13%), liposarcoma (10%), and malignant fibrous histiocytoma (10%). In all, 61% received single‐agent chemotherapy, usually doxorubicin. An objective response was reported in 33% of patients (53% in those with synovial sarcoma); 22% had stable disease and 45% derived ‘clinical benefit’ (objective responses + stable disease for ≥6 months). Median duration of response was 9 months and median posttreatment overall survival (OS) was 12 months. In multivariate analysis, age <40 years, liposarcoma, and synovial histology were found to be positive, and bone involvement to be negative, independent prognostic factors. Patients treated with combination chemotherapy experienced longer OS than those treated with a single agent. CONCLUSIONS.: Palliative chemotherapy may be beneficial in approximately half of patients with advanced STS. Synovial sarcoma and liposarcoma subtypes have a better prognosis. However, the overall poor outcome of these patients indicates the need to continue the search for more effective agents. Cancer 2008. © 2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Judson, I., Verweij, J., Gelderblom, H., Hartmann, J. T., Schöffski, P., Blay, J.-Y., Kerst, J. M., Sufliarsky, J., Whelan, J., Hohenberger, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70063-4 · Cited by 1,183
Self-citationSeddon, B., Strauss, S. J., Whelan, J., Leahy, M., Woll, P. J., Cowie, F., Rothermundt, C., Wood, Z., Benson, C., Ali, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30622-8 · Cited by 528
Self-citationUK guidelines for the management of soft tissue sarcomas
Dangoor, A., Seddon, B., Gerrand, C., Grimer, R., Whelan, J., & Judson, I. (2016) · Clinical Sarcoma Research · doi:10.1186/s13569-016-0060-4 · Cited by 477
Self-citationGuidelines for the Management of Soft Tissue Sarcomas
Grimer, R., Judson, I., Peake, D., & Seddon, B. (2010) · Sarcoma · doi:10.1155/2010/506182 · Cited by 432
Self-citationChawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., Butrynski, J. E., Adkins, D. R., Hendifar, A. E., Kroll, S., & Ganjoo, K. N. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3660 · Cited by 155
“Conclusion PFS, overall survival, and tumor response compared favorably with historical outcomes achieved with other first-line chemotherapies for advanced STS.”
BackgroundInfluential
Metadata
- Authors
- Karavasilis, V., Seddon, B. M., Ashley, S., Al‐Muderis, O., Fisher, C., & Judson, I.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-03-19
- Volume
- 112
- Issue
- 7
- Pages
- 1585-1591
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2032646205
- Cited by
- 214
- References
- 0
- FWCI
- 9.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcoma: Retrospective analysis and identification of prognostic factors in 488 patients. https://app.cochat.ai/papers/10.1002/cncr.23332
- The paper
- Karavasilis, V., Seddon, B. M., Ashley, S., Al‐Muderis, O., Fisher, C., & Judson, I. (2008). Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcoma: Retrospective analysis and identification of prognostic factors in 488 patients. Cancer. https://doi.org/10.1002/cncr.23332
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.